Company news

Share this article:
According to an internal memo, Pfizer is planning to end manufacturing of heart disease medications, Forbes reported, while also scaling back development of anemia, osteoporosis, liver, muscle, obesity and peripheral artery disease treatments. The company will instead focus on five therapeutic areas: Alzheimer's; diabetes, immune disorders and inflammation; cancer; pain and mental illness.

In an effort to control costs, GlaxoSmithKline may cut as many as 850 R&D jobs in the US and UK, according to a Wall Street Journal report.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.